• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$7.51 $0.11 (1.49%)

REAL-TIME: Last trade at

Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Jump to this page for:

Related Resources

Rigel Pharmaceuticals expands respiratory franchise with two drug candidates

5/16/2012 by Theflyonthewall.com

Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease

5/16/2012 by PR Newswire

Rigel Pharmaceuticals reports Q1 EPS (32c), consensus (31c)

5/1/2012 by Theflyonthewall.com

Rigel Announces First Quarter 2012 Financial Results

5/1/2012 by PR Newswire

Summer Street's pharmaceuticals analyst research team holds conference call

4/30/2012 by Theflyonthewall.com

5 Biotech Stocks To Boost Your Portfolio

4/22/2012 by Seeking Alpha

Piper Jaffray's biotech and specialty pharma analysts hold a conference call

4/5/2012 by Theflyonthewall.com

Abbott’s Hep-C Pressures All Hep-C Rivals (ABT, RIGL, GILD, VRTX, IDIX)

4/4/2012 by 24/7 Wall Street

Rigel Pharma: Build Positions On Potential Positive Results From RA Study

4/3/2012 by iStockAnalyst

Lazard Capital to host a bus tour

4/3/2012 by Theflyonthewall.com

Rigel Pharma likely to report positive fostamatinib results, says Oppenheimer

4/3/2012 by Theflyonthewall.com

Canaccord Genuity Starts Rigel Pharmaceuticals (RIGL) at Hold

3/26/2012 by StreetInsider.com

Rigel Pharmaceuticals management to meet with BMO Capital

3/21/2012 by Theflyonthewall.com

Rigel Pharmaceuticals files to sell $200M in common stock and warrants

3/8/2012 by Theflyonthewall.com

Rigel's Fourth Quarter In Line, Fostamatinib Still On Schedule for New Drug Application in 2013

3/6/2012 by Morningstar

Rigel Pharmaceuticals reports Q4 EPS (36c), consensus (28c)

3/6/2012 by Theflyonthewall.com

Rigel Announces Fourth Quarter and Year End 2011 Financial Results

3/6/2012 by PR Newswire

Rigel Announces Participation at Two Investor Conferences

2/23/2012 by PR Newswire

Citi Upgrades Rigel Pharmaceuticals (RIGL) to Buy

2/22/2012 by StreetInsider.com

Rigel Pharmaceuticals upgraded to Buy from Neutral at Citigroup

2/22/2012 by Theflyonthewall.com

Rigel Pharma Has More Room To Run

2/6/2012 by Seeking Alpha

Two Rigel Pharma (RIGL) Lead Product Candidates Entered Trials in Q411

1/5/2012 by StreetInsider.com

Rigel Pharmaceuticals initiates clinical trials for two product candidates

1/5/2012 by Theflyonthewall.com

Rigel Pharmaceuticals reports Q2 EPS 38c vs. consensus 39c

1/5/2012 by Theflyonthewall.com

Rigel Announces Initiation of Clinical Trials in Two Immunology Programs

1/5/2012 by PR Newswire

The 2 Best-Performing Sectors Over the Last Decade

12/20/2011 by The Motley Fool

Covidien Spins Off Drug Company: 5 Drug Makers Hedge Funds Want Most

12/16/2011 by The Motley Fool

The New Pfizer: 6 Drug Companies With Bullish Short Trends

12/13/2011 by The Motley Fool

Rigel to Present at Oppenheimer Annual Healthcare Conference

12/7/2011 by PR Newswire

Cramer Does His Homework

12/1/2011 by CNBC Video

Rigel Pharmaceuticals management to meet with BMO Capital

11/22/2011 by Theflyonthewall.com

Rigel Pharma shares should be bought ahead of Oskira data, says BMO Capital

11/10/2011 by Theflyonthewall.com

Rigel to Participate at Two Upcoming Investor Conferences

11/3/2011 by PR Newswire

Rigel Pharma posts 3Q loss as revenue falls

11/1/2011 by Bioscience Technology

Rigel Pharmaceuticals Inc. Reports Operating Results (10-Q)

11/1/2011 by GuruFocus

Rigel Pharmaceuticals, Inc. (RIGL) Reports Q3 Loss of $0.25

11/1/2011 by StreetInsider.com

Rigel Pharmaceuticals reports Q3 EPS (25c) vs. consensus (30c)

11/1/2011 by Theflyonthewall.com

Rigel Announces Third Quarter 2011 Financial Results

11/1/2011 by PR Newswire

Mini J&J? I Guess Not

10/20/2011 by The Motley Fool

Piper Jaffray's biotech and specialty pharma analysts hold a conference call

10/17/2011 by Theflyonthewall.com
See More Articles...